Abstract
Precision oncology has reached a milestone as data from two trials in which molecular profiling guided both site-specific and tumour-agnostic therapies indicate improved survival outcomes in patients with cancer of unknown primary. These findings can also be extrapolated and support the use of tissue-agnostic approaches in general, and also suggest that the tissue of origin might have a role in the agnostic classification of cancers and their response to treatment.
Original language | English |
---|---|
Journal | Nature Reviews Clinical Oncology |
DOIs |
|
Publication status | Accepted/In press - 1 Jan 2024 |